Drug intelligence / Profile preview

MT-009

Development stage: Preclinical
Lead developer: Marigold Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MT-009 is a discovery-stage bispecific antibody-drug conjugate (Bs-ADC) being developed by Marigold Therapeutics. It is designed to target multiple antigens simultaneously to improve selectivity and efficacy in solid tumors, particularly those harboring Ras mutations. The drug is currently being investigated for the treatment of colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC). As a bispecific ADC, MT-009 likely utilizes a dual-targeting approach to enhance internalization and payload delivery to tumor cells while minimizing off-target toxicity.

Targets

KLRB1 (C-type lectin-like receptor CD161)

Beyond the preview

Go deeper on MT-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-009.

Explore the full profile